Bernard Gilly (GenSight Biologics S.A. (Euronext: SIGHT))

Gilly, Bernard (GenSight Biologics 201304 CEO + Co-founder before Fovea + Sofinnova Partners + Transgene)

	Organisation	GenSight Biologics S.A. (Euronext: SIGHT)
	Product	BIOTECH
	Product 2	venture capital

Record changed: 2020-12-06

Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

More documents for Bernard Gilly

[1] GenSight Biologics S.A.. (10/22/20). "Press Release: GenSight Biologics Successfully Raises €25 Million in an Oversubscribed Private Placement With US and European Institutional Investors". Paris....
[2] GenSight Biologics S.A.. (4/3/18). "Press Release: GenSight Biologics Announces Topline Results from REVERSE Phase III Clinical Trial of GS010 in Patients with Leber Hereditary Optic Neuropathy (LHON)". Paris....
[3] GenSight Biologics S.A.. (8/1/17). "Press Relase: GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy". Paris....
[4] Euronext N.V.. (7/13/16). "Press Release: GenSight Biologics Lists on Euronext to Become Europe's First Listed Gene Therapy Company. €40 Million Raised, Market Capitalisation €149 Million". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

» top

Top News

Upcoming Events

Management Appointments

Financings & Acquisitions

Collaborations & Licensing

At Investor Conferences

Bio Regions & Life Sciences Clusters

Business Parks & Science Centres

Associations

Advertise

Bernard Gilly (GenSight Biologics S.A. (Euronext: SIGHT))

More documents for Bernard Gilly